Fintel reports that on January 29, 2025, HC Wainwright & Co. downgraded their outlook for Leap Therapeutics (NasdaqCM:LPTX) ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Durect (DRRX – Research Report) today. The company’s shares opened today at ...

H.C. Wainwright analyst Ed Arce keeps a Neutral rating on Durect (DRRX) without a price target after the company announced that data from the ...

H.C. Wainwright adjusted its stance on Leap Therapeutics (NASDAQ:LPTX), downgrading the biopharmaceutical company's stock ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.11% ...

Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Immunocore in a research report issued to ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 28.87% ...

On Wednesday, H.C. Wainwright reaffirmed a Buy rating on shares of TG Therapeutics (NASDAQ:TGTX) shares with a steady price target of $55.00. The firm's analyst highlighted the company's strong ...

On Tuesday, H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) stock with a steady price target of $7.50, significantly above the current trading price of $1.88. The firm's ...

H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% ...